An observational study in Asthma, sponsored by Connecticut Children's Medical Center. Completed at 1 site in United States. Open to participants aged 4 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Connecticut Children's Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,696 studies in Asthma with a site in United States — 135 open to participants now, 189 under way, 19 of them phase 3. Asthma · United States.
Among the 1,696 studies in Asthma with a site in United States, this one is the 242nd largest by enrollment of the 330 observational ones that give a count, is one of 49 that started in 2020, is one of 335 observational ones, and was the 1,253rd registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →135 of the 1,696 studies in Asthma with a site in United States are open now. Recruiting first, the newest first:
University of California, Berkeley · Sites in United States
Ages 13+
Janssen Research & Development, LLC · Sites in United States, Argentina, China and 2 more countries
Ages 18–85
Pfizer · Sites in United States, Puerto Rico
Ages 12–80
GlaxoSmithKline · Sites in United States, Argentina, Canada and 1 more country
Ages 18+
Spiro Medical, Inc. · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 4 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,696 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 151 · Phase 2 338 · Phase 3 276 · Phase 4 158
First in 1990; this study’s year is marked. 49 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is below the median of 159 across 1,254 observational studies indexed under Asthma.
Median enrollment 100 across the 1,354 interventional studies, 112 across the 330 observational. Of the 1,402 that completed or were terminated, 626 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
643 of 1,696 have an industry lead sponsor. The 10 most frequent:
Connecticut Children's Medical Center is the lead sponsor of 59 studies on the registry; 13 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
Connecticut Children's Medical Center has 3 studies filed under Asthma — fewer than ten, so there is no comparison to draw.
84 of the studies in Asthma with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT07645248Phase 3GlaxoSmithKlineA Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a) | 2026-12-28 |
| NCT06052267Phase 3Teva Branded Pharmaceutical Products R&D LLCA Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | 2026-12-31 |
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
| NCT07671001Phase 3GlaxoSmithKlineA Study of Depemokimab in Participants of 6 to 11 Years of Age | 2027-03-01 |
Add all 84 to your calendar (.ics) → With an account.
Among the 1,696 studies in Asthma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main hypothesis of this study is to see if children and adolescents with poorly controlled asthma will find the Propeller electronic monitoring device is feasible and acceptable, and will result in improved medication adherence and asthma control. Preliminary studies indicate that Propeller can improve medication adherence rates in children with asthma and reduce the number of days of reliever medication used. It also has been shown to reduce missed days of school and hospitalizations due to asthma exacerbations. The Propeller device is a sensor that fits over inhalers and uses Bluetooth connection to cell phones to remind patients to take their medication. It also records use of the controller and rescue inhalers, allowing for parents, physicians, and patients to get a fuller and more accurate picture of their adherence to treatment and severity of disease. With improved adherence, asthma control should improve, resulting in a decreased costs and use of services.
This study is a prospective cohort study using a pre-/post-design.
The target population consists of children and adolescents 10-18 years old making an ED visit or admitted to the hospital at Connecticut Children's Medical Center for an asthma exacerbation.
All patients will receive two Propeller devices (for controller and rescue inhalers), an App for their smartphone, and a free Propeller subscription, which provides access support and services, and hardware and software updates. Only the children and adolescents involved with the study will have the app on their phone. The parents will not put the Propeller app on their phone. Families will be asked to share the study information with their primary care provider and will be provided with an introductory letter to bring to the provider, if they so choose.
Data collection will begin at enrollment and will continue through the three-month follow-up period. Propeller provides the option of continuous monitoring and data collection beyond study cessation.
Data uploads to the portal occur automatically for patients and caregivers who have installed the Propeller App on their smartphone. Additionally, patients' primary-care providers will receive a password allowing them to track and access participants' dashboard. Patients will bring a letter to their primary-care provider explaining that they are part of a study of Propeller's device, and receive instructions on how to view the dashboard and adherence data.
At enrollment, participants and parents will complete the Test of Adherence to Inhalers (TAI), Asthma Control Test (ACT) and PedsQL, along with providing baseline medical history/asthma history data and sociodemographic. The TAI, ACT and PedsQL surveys will again be completed one and three months post enrollment information. Additionally, participants will answer an adapted AMDAT survey that will be used to provide acceptability data about the Propeller device.
The criteria were revised on the registry on Oct 19, 2026. See what changed
The target population consists of children and adolescents 4-18 years old making an ED visit or admitted to the hospital at Connecticut Children's Medical Center for an asthma exacerbation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The subject has an inhaler medication besides the following, given these are the current medications compatible with the Propeller EMD.
i. Advair HFA ii. Flovent HFA iii. QVAR HFA v. Ventolin HFA vi. ProAir HFA
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All enrolled participants will be given the Propeller Smart Inhaler electronic monitoring device to use for three months to track how often they are using their inhalers either for their regular medication or as a rescue dose.
Other: Propeller EMD
Propeller electronic monitoring device is a sensor that fits on top of inhalers and uses Bluetooth connection to cell phones to remind patients to take their medication.
Propeller Device Use at Three Months
Device use will be assessed by recording the number and percentage of children and adolescents still using the Propeller electronic monitoring device at 3 months following enrollment.
Time frame: 3 months
Acceptability of the Propeller EMD as Determined by the Electronic Medical Devices Assessment Toolkit (AMDAT)
Acceptability of the Propeller electronic monitoring device will be assessed through phone interviews and participant survey responses using the modified Adolescent Medical Devices Assessment Toolkit (AMDAT). Surveys will be administered at baseline, 1 month, and 3 months following enrollment to assess user experience, usability, and comfort using the device.
Time frame: Baseline, 1 month, and 3 months
Device Use at One Month
Device use will be assessed by recording the number and percentage of children and adolescents using the Propeller electronic monitoring device at 1 month following enrollment.
Time frame: 1 month
Asthma Control Test (ACT) Score
Asthma control will be measured using the Asthma Control Test (ACT), a validated questionnaire with scores ranging from 0 to 25, where higher scores indicate better asthma control. ACT will be assessed at baseline, 1 month, and 3 months after enrollment. Changes in ACT score over time will be evaluated, with a change of 3 or more points considered clinically meaningful.
Time frame: 1 month and 3 months
Medication Adherence Measured by Propeller Device
EMD adherence was calculated for the intervention group after enrollment. Real-time inhaled corticosteroid (ICS) administration information (number of, time and date of puffs actuated) was obtained. Daily rate of adherence measured by EMD was defined as the number of actuated puffs on each day divided by the expected number of puffs, maxed at 100% to avoid overestimation due to intentional "dumping" or unintentional over-usage of medication. Average EMD adherence was calculated at 3 months.
Time frame: 3 months
Participants were recruited from inpatient units, emergency department visits, pulmonary clinics, and primary care clinics at Connecticut Children's Medical Center. Potential participants were identified through EPIC logs and approached in person or contacted by phone. A total of 1,113 individuals were screened, of whom 42 were enrolled. Reasons for non-enrollment included ineligibility, lack of interest, inability to contact, and incompatible inhaler devices.
| Milestone | Propeller Smart Inhaler EMD |
|---|---|
| Started | 42 |
| Completed | 14 |
| Not completed | 28 |
| Withdrew: Lost to follow-up | 8 |
| Withdrew: Disconnected device | 1 |
| Withdrew: Unable to contact | 1 |
| Withdrew: Did not complete study procedures | 18 |
Device use will be assessed by recording the number and percentage of children and adolescents still using the Propeller electronic monitoring device at 3 months following enrollment.
| Participants | Propeller Smart Inhaler EMD |
|---|---|
| Propeller Device Use at Three Months | 14 |
Acceptability of the Propeller electronic monitoring device will be assessed through phone interviews and participant survey responses using the modified Adolescent Medical Devices Assessment Toolkit (AMDAT). Surveys will be administered at baseline, 1 month, and 3 months following enrollment to assess user experience, usability, and comfort using the device.
| Participants | Propeller Smart Inhaler EMD |
|---|---|
| Participants reporting device was easy to use | 13 |
| Comfortable using device in front of peers | 13 |
| Would continue using device | 12 |
Device use will be assessed by recording the number and percentage of children and adolescents using the Propeller electronic monitoring device at 1 month following enrollment.
| Participants | Propeller Smart Inhaler EMD |
|---|---|
| Device Use at One Month | 17 |
Asthma control will be measured using the Asthma Control Test (ACT), a validated questionnaire with scores ranging from 0 to 25, where higher scores indicate better asthma control. ACT will be assessed at baseline, 1 month, and 3 months after enrollment. Changes in ACT score over time will be evaluated, with a change of 3 or more points considered clinically meaningful.
| Score on a scale | Propeller Smart Inhaler EMD |
|---|---|
| ACT Score at 1 Month | 19.7 (15 to 24) |
| ACT Score at 3 Months | 24 (20 to 25) |
EMD adherence was calculated for the intervention group after enrollment. Real-time inhaled corticosteroid (ICS) administration information (number of, time and date of puffs actuated) was obtained. Daily rate of adherence measured by EMD was defined as the number of actuated puffs on each day divided by the expected number of puffs, maxed at 100% to avoid overestimation due to intentional "dumping" or unintentional over-usage of medication. Average EMD adherence was calculated at 3 months.
| percent | Propeller Smart Inhaler EMD |
|---|---|
| Medication Adherence Measured by Propeller Device | 54 ± 28 |
Collected over From enrollment until study completion, up to 12 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Propeller Smart Inhaler EMD | 0/42 (0%) | 0/42 (0%) | 0/42 (0%) |
The baseline analysis population includes all participants who were enrolled in the study (N=42). Baseline characteristics were collected at enrollment prior to initiation of the Propeller electronic monitoring device. Participants who did not complete follow-up assessments were still included in the baseline analysis.
| Age, Customized(Participants) | Propeller Smart Inhaler EMD |
|---|---|
| Pediatric patients — Age 4-7 years | 19 |
| Pediatric patients — Ages 8-11 years | 16 |
| Pediatric patients — Age 12-15 years | 4 |
| Pediatric patients — Age 16-18 years | 3 |
| Sex: Female, Male(Participants) | Propeller Smart Inhaler EMD |
|---|---|
| Female | 22 |
| Male | 20 |
| Race/Ethnicity, Customized(Participants) | Propeller Smart Inhaler EMD |
|---|---|
| Race/Ethnicity — Asian | 0 |
| Race/Ethnicity — Black/African American | 12 |
| Race/Ethnicity — Hispanic/Latino | 16 |
| Race/Ethnicity — White | 9 |
| Race/Ethnicity — Unknown | 5 |
| Asthma control Test (ACT) Score(ACT score) | Propeller Smart Inhaler EMD |
|---|---|
| Mean | 20.7 (14 to 25) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2020 to primary completion in Jul 2023, 32 months.
Results were first posted in Oct 2026, 3 years 2 months after primary completion.
Of 366 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's 32 months is below that.
Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Connecticut Children's Medical Center